Endothelial Nitric Oxide Synthase (NOS3)

📖 Wiki Page

protein1631 wordssynced 2026-04-02

Endothelial Nitric Oxide Synthase (NOS3/eNOS)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Endothelial Nitric Oxide Synthase (NOS3)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>NOS3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Endothelial Nitric Oxide Synthase (NOS3)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=NOS3" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/hepatitis" style="color:#ef9a9a">Hepatitis</a>, <a href="/wiki/ischemia" style="color:#ef9a9a">Ischemia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">198 edges</a></td>
</tr>
</table>

Pathway Diagram

...

Endothelial Nitric Oxide Synthase (NOS3/eNOS)

Pathway Diagram

Mermaid diagram (expand to render)

Overview

NOS3 (Endothelial Nitric Oxide Synthase, also called eNOS) is a 1157-amino acid enzyme primarily expressed in vascular endothelial cells where it catalyzes the production of nitric oxide (NO) from L-arginine. NOS3 is a calcium/calmodulin-dependent enzyme that plays critical roles in regulating vascular tone, blood pressure, cerebral blood flow, and blood-brain barrier (BBB) integrity [@katusic2009].

The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, depends on proper NOS3 function for maintaining cerebral perfusion and neural homeostasis. Dysregulation of NOS3 contributes to the vascular dysfunction observed in Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and vascular cognitive impairment (VCI) [@van2006][@girouard2006].

Nitric oxide produced by NOS3 acts as a signaling molecule that:

Relaxes vascular smooth muscle to increase blood flow
Inhibits platelet adhesion and aggregation
Protects against atherosclerosis
Regulates blood-brain barrier function
Modulates neuroinflammatory responses
Affects synaptic plasticity and memory formation

Molecular Biology

Structure and Domains

NOS3 is a modular enzyme with distinct functional domains:

N-terminal oxygenase domain (1-490 aa): Contains binding sites for heme, tetrahydrobiopterin (BH4), and L-arginine substrate
Calmodulin-binding domain (510-560 aa): Mediates calcium-dependent activation
C-terminal reductase domain (561-1157 aa): Contains binding sites for FAD, FMN, and NADPH electron donors

The enzyme requires multiple cofactors for activity:

Heme (Fe3+) - required for catalysis
Tetrahydrobiopterin (BH4) - essential for coupling and preventing uncoupling
FAD and FMN - electron transfer from NADPH to heme
Calmodulin - calcium sensor that activates the enzyme

Expression and Localization

NOS3 is primarily expressed in:

Vascular endothelial cells - lining all blood vessels
Plasma membrane - caveolae-mediated localization
Golgi apparatus - perinuclear pool
Neurons - lower levels, for synaptic plasticity
Astrocytes - some expression, contributes to neurovascular coupling

In the brain, NOS3 is enriched in:

Cerebral cortex microvasculature
Hippocampal blood vessels
Choroid plexus
Meningeal vessels

Regulation

NOS3 activity is regulated at multiple levels:

Transcriptional regulation: Estrogen, shear stress, and hypoxia modulate NOS3 expression

Post-translational modification: Phosphorylation (Ser1177 in humans), acylation, S-nitrosylation

Subcellular localization: Caveolin-1 binding inhibits activity; calmodulin displacement activates

Cofactor availability: BH4 levels critically affect enzyme function

Substrate availability: L-arginine levels influence NO production

Normal Function

Vascular Homeostasis

NOS3-derived nitric oxide maintains vascular health through several mechanisms:

Vasodilation: NO diffuses to vascular smooth muscle cells, activating guanylyl cyclase and increasing cGMP, leading to relaxation and increased blood flow. This is the basis for the therapeutic use of nitrates in cardiovascular disease [@katusic2009].

Anti-inflammatory: NO inhibits leukocyte adhesion to endothelial cells by downregulating adhesion molecule expression (VCAM-1, ICAM-1, E-selectin).

Anti-proliferative: NO suppresses vascular smooth muscle cell proliferation, maintaining vessel wall integrity.

Antioxidant: NO can act as an antioxidant, scavenging reactive oxygen species (ROS).

Cerebral Blood Flow Regulation

NOS3 is critical for regulating cerebral blood flow (CBF):

Neurovascular coupling: Neural activity triggers increased CBF through NOS3-mediated vasodilation. This process, called functional hyperemia, ensures adequate oxygen and glucose delivery to active brain regions. Astrocyte endfeet processes sense neuronal activity and signal to endothelial cells via NOS3 [@girouard2006][@iadecola2009].

Autoregulation: NOS3 helps maintain relatively constant CBF despite changes in systemic blood pressure, protecting the brain from hypo- or hypertension.

CO2 reactivity: NOS3 mediates CBF responses to changes in arterial CO2 partial pressure, an important physiological response.

Blood-Brain Barrier Integrity

NOS3 plays a dual role in BBB regulation:

Baseline maintenance: Low-level NO production helps maintain BBB tight junction integrity through cGMP-dependent signaling.

Permeability modulation: Excessive NOS3 activation or uncoupling leads to increased BBB permeability, potentially allowing harmful substances into the brain.

Role in Neurodegenerative Diseases

Alzheimer's Disease

NOS3 dysfunction is intimately linked to AD pathogenesis through multiple mechanisms:

Cerebral hypoperfusion: Reduced NOS3 activity leads to decreased cerebral blood flow, observed in early AD. This chronic hypoperfusion contributes to neuronal dysfunction and may accelerate amyloid pathology [@kim2008][@van2006].

Amyloid-β interaction: Amyloid-β peptides directly impair NOS3 function through several mechanisms:

Reducing NOS3 phosphorylation at Ser1177
Increasing NOS3 uncoupling
Promoting oxidative inactivation of BH4
Enhancing endothelial cell apoptosis

The resulting NO deficiency creates a vicious cycle where reduced perfusion increases amyloid production while amyloid further impairs NOS3 [@takano2007][@kelley2018].

Neurovascular unit dysfunction: AD affects all components of the neurovascular unit. NOS3 impairment contributes to:

Blood-brain barrier breakdown
Reduced amyloid clearance
Diminished neurovascular coupling
Cerebral amyloid angiopathy

Therapeutic implications: Enhancing NOS3 activity is being explored as an AD therapeutic strategy. Statins, which upregulate NOS3, have shown some promise in epidemiological studies [@kim2008][@zlokovic2011].

Parkinson's Disease

NOS3 contributes to PD pathogenesis through vascular and non-vascular mechanisms:

Cerebral hypoperfusion: Reduced NOS3 activity and cerebral blood flow are observed in PD patients, particularly in the substantia nigra and basal ganglia [@wang2006].

Dopaminergic neuron vulnerability: The high metabolic activity of dopaminergic neurons makes them particularly dependent on adequate blood supply. NOS3-mediated dysregulation may contribute to their selective vulnerability.

Neuroinflammation: NOS3 interacts with neuroinflammatory processes in PD. While low-level NO may be protective, excessive production from inducible NOS (iNOS) contributes to dopaminergic toxicity.

L-DOPA response: Some studies suggest NOS3 polymorphisms affect response to L-DOPA therapy in PD patients [@wang2006].

Stroke and Ischemic Injury

NOS3 has complex, time-dependent effects in stroke:

Protective effects: Before and immediately after ischemia, NOS3-derived NO helps maintain cerebral perfusion and protects neurons through antioxidant and anti-apoptotic mechanisms.

Detrimental effects: During reperfusion, NOS3 can contribute to oxidative stress and blood-brain barrier disruption through peroxynitrite formation when NO reacts with superoxide.

Therapeutic window: Timing of NOS3 modulation is critical. NOS3 enhancers given before stroke or very early after onset may be beneficial [@liu2019].

Vascular Cognitive Impairment (VCI)

NOS3 is central to VCI pathogenesis:

Small vessel disease: NOS3 dysfunction contributes to cerebral small vessel disease, including white matter lesions and lacunes, which are major contributors to VCI [@pantoni2010].

Vascular risk factors: Hypertension, diabetes, and hyperlipidemia all impair NOS3 function, creating vascular cognitive vulnerability.

White matter integrity: NOS3-mediated regulation of cerebral blood flow is essential for white matter maintenance. Chronic hypoperfusion leads to white matter damage and cognitive decline [@osullivan2018].

Strategic infarcts: NOS3-related vascular dysfunction may promote strategically placed infarcts that disproportionately affect cognition.

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): Some studies find altered NOS3 expression in ALS motor cortex and spinal cord, potentially contributing to vascular compromise.

Huntington's Disease (HD): NOS3 polymorphisms may modify age of onset and disease progression in HD.

Multiple Sclerosis (MS): NOS3 dysregulation affects blood-brain barrier integrity and lesion formation in MS.

Therapeutic Approaches

NOS3 Enhancers

Statins: HMG-CoA reductase inhibitors upregulate NOS3 expression and activity, improving endothelial function. Atorvastatin and rosuvastatin have been studied in AD and vascular cognitive impairment.

L-arginine supplementation: Substrate enhancement may boost NO production, though results have been mixed.

BH4 supplementation: Restoring BH4 levels may improve NOS3 coupling, particularly in states of oxidative stress.

Phosphodiesterase inhibitors: Drugs like sildenafil (which increase cGMP) enhance NOS3-mediated signaling downstream of NO production.

NOS3-Targeted Strategies

Gene therapy: Delivering NOS3 genes to enhance endothelial NO production is in development for cardiovascular disease and potentially for neurodegeneration.

Nanoparticle delivery: Targeted nanoparticles could deliver NOS3-activating compounds specifically to cerebral endothelium.

Antioxidants: Protecting NOS3 from oxidative inactivation by scavenging ROS.

Interactions and Signaling Pathways

Protein Interactions

Caveolin-1 (CAV1): Inhibits NOS3 when bound; displacement by calmodulin activates the enzyme
Calmodulin (CALM1): Calcium sensor that activates NOS3
Heat shock protein 90 (HSP90): Facilitates NOS3 signaling
Akt/PKB: Phosphorylates and activates NOS3 at Ser1177
AMP-activated protein kinase (AMPK): Activates NOS3
G-protein coupled receptors: Many activate NOS3 through Akt-dependent pathways

Signaling Pathways

cGMP/PKG pathway: NO activates soluble guanylyl cyclase, increasing cGMP
PI3K/Akt pathway: Growth factor signaling to NOS3
MAPK pathway: Stress-activated signaling affects NOS3
Estrogen signaling: Estrogen receptors upregulate NOS3 expression

Cross-Links

[NOS3 Gene](/genes/nos3) - Gene page
[Nitric Oxide](/entities/nitric-oxide) - Signaling molecule
[Blood-Brain Barrier](/mechanisms/blood-brain-barrier) - Related pathway
[Alzheimer's Disease](/diseases/alzheimers-disease) - Disease context
[Parkinson's Disease](/diseases/parkinsons-disease) - Disease context
[Cerebral Blood Flow](/mechanisms/cerebral-blood-flow) - Related mechanism
[Vascular Cognitive Impairment](/diseases/vascular-cognitive-impairment) - Disease context

References

[Kim et al, Endothelial nitric oxide synthase and Alzheimer's disease, J Neurol Sci (2008)](https://pubmed.ncbi.nlm.nih.gov/18572167/)

[Katusic et al, Vascular protection by endothelial nitric oxide synthase, J Mol Cell Cardiol (2009)](https://pubmed.ncbi.nlm.nih.gov/18729729/)

[van Gool et al, The role of nitric oxide in Alzheimer's disease, J Alzheimers Dis (2006)](https://pubmed.ncbi.nlm.nih.gov/16504407/)

[Edwards et al, Endothelial nitric oxide synthase and vascular dementia, Stroke (2010)](https://pubmed.ncbi.nlm.nih.gov/20165947/)

[Stavropoulos S, et al, eNOS dysfunction in Alzheimer's disease, J Cereb Blood Flow Metab (2019)](https://pubmed.ncbi.nlm.nih.gov/31734817/)

[Girouard H, et al, Neurovascular coupling in Alzheimer's disease, Nat Rev Neurosci (2006)](https://pubmed.ncbi.nlm.nih.gov/16829954/)

[Iadecola C, et al, Neurovascular dysfunction, amyloid and Alzheimer's disease, Prog Neurobiol (2009)](https://pubmed.ncbi.nlm.nih.gov/19545561/)

[Zlokovic BV, et al, Neurovascular pathways and Alzheimer's disease, Nat Rev Neurol (2011)](https://pubmed.ncbi.nlm.nih.gov/22057333/)

[Takano T, et al, Amyloid-beta and neurovascular dysfunction, Nat Med (2007)](https://pubmed.ncbi.nlm.nih.gov/17629852/)

[Wang L, et al, Nitric oxide and Parkinson's disease, Prog Neuropsychopharmacol Biol Psychiatry (2006)](https://pubmed.ncbi.nlm.nih.gov/16263247/)

[Chen X, et al, eNOS and cerebral blood flow in aging, J Neurochem (2020)](https://pubmed.ncbi.nlm.nih.gov/32061149/)

[Liu H, et al, Nitric oxide synthase in stroke, Stroke (2019)](https://pubmed.ncbi.nlm.nih.gov/30661531/)

[Hanson LR, et al, Neurovascular coupling impairment in PD, Mov Disord (2019)](https://pubmed.ncbi.nlm.nih.gov/31267681/)

[Pantoni L, et al, Cerebral small vessel disease and vascular cognitive impairment, Lancet Neurol (2010)](https://pubmed.ncbi.nlm.nih.gov/20078942/)

[O'Sullivan M, et al, MRI markers of vascular cognitive impairment, Neurology (2018)](https://pubmed.ncbi.nlm.nih.gov/29440490/)

[Romberg C, et al, eNOS knockout mice and memory, Behav Brain Res (2011)](https://pubmed.ncbi.nlm.nih.gov/21219979/)

[Kelley CM, et al, eNOS and amyloid interplay in Alzheimer's, Acta Neuropathol Commun (2018)](https://pubmed.ncbi.nlm.nih.gov/30420219/)

[Lane CA, et al, Vascular dysfunction in Alzheimer's disease, Brain Pathol (2019)](https://pubmed.ncbi.nlm.nih.gov/30663291/)

[Sweet AD, et al, Nitric oxide and blood-brain barrier in neurodegeneration, J Neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31064392/)

[Sachdev P, et al, Vascular cognitive impairment, J Neurol Sci (2013)](https://pubmed.ncbi.nlm.nih.gov/23651402/)

External Links

[UniProt: Q9UHD5](https://www.uniprot.org/uniprot/Q9UHD5)
[GeneCards: NOS3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NOS3)
[NCBI Gene: NOS3](https://www.ncbi.nlm.nih.gov/gene/4846)
[PDB: 1M9J](https://www.rcsb.org/structure/1M9J) - NOS3 heme domain structure

Pathway Diagram

The following diagram shows the key molecular relationships involving Endothelial Nitric Oxide Synthase (NOS3) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →